drugset / Trial / NCT04958031
A Trial of the Safety, Tolerability, and Pharmacodynamics of CVL-871 in Subjects With Dementia-Related Apathy
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to determine whether CVL-871 is safe and tolerable in patients with Dementia-Related Apathy and if CVL-871 shows changes in clinical measurements of apathy.
Timeline
- Start
- 2021-06-22
- Primary completion
- 2025-02-12
- Completion
- 2025-02-12
Outcome
Outcome not reported
Stopped (Business): “Sponsor Decision - Not Safety Related”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RAZPIPADON | Small molecule | 1 mg | Oral |
| Subject | RAZPIPADON | Small molecule | 3 mg | Oral |
Indications
No indication recorded.